
Trial News

February 2002

ANGLO CELTIC COOPERATIVE ONCOLOGY GROUP

Dear Colleagues,

Anglo Celtic I

Follow-up information continues to arrive, thanks to everyone involved. The number of events to date is **241** and a poster has been submitted to ASCO for this year.

Anglo Celtic II

Accrual for Anglo Celtic II has now been closed to recruitment. The total number of patients at close of play was **362** and the final graph is shown on the back of the Newsletter. A poster has been submitted for ASCO this year.

Anglo Celtic III:


SPROG (Secondary **PRO**phylaxis with **G-CSF**)

10 centres currently have LREC approval and 9 patients have been entered to date. Protocol amendment number 01 has now been approved by MREC. This amendment to the protocol will allow neo-adjuvant patients and patients in the synchronous arm of the **SECRAB** trial to be entered into **SPROG**. If you would like further information about this trial please contact Kirsten Murray at SCTN. Remember that **SPROG** is compatible with the **TACT** and **TANGO** trials.

Anglo Celtic IV

“Will Weekly Work”

At the last Anglo Celtic meeting Mark Verrill and Dave Cameron proposed a trial comparing the activity and safety of a weekly vs 3-weekly Paclitaxel treatment schedule in patients with advanced or metastatic breast cancer. Protocols for this trial should be available soon and I will be asking for “Intent to Participate”.



Intensive Chemotherapy in Breast Cancer

Next Meeting

Professor Leonard hosted the last meeting in Swansea. It was a great success despite the problems of traveling to deepest Wales!! The next meeting will be in Cambridge, courtesy of Dr Helena Earl. The date of the meeting is May 3rd and will be held in Downing College.

Other Trials

p53

The p53 trial has now been approved by MREC and LREC packs were sent out to interested centers at the end of January. If you would like to take part in this trial or would like any further information please contact Kirsten Murray at SCTN.

Hera

The **HERA** trial has now received MREC approval for amendment B. LREC packs will be sent out to all investigators as soon as possible.

Tango

5 centres now have LREC approval, Western General (Edinburgh), Beatson (Glasgow), Singleton (Swansea), Northampton and Crosshouse (Ayrshire). 5 patients have been randomized through SCTN to date.

Dr Liz Foster

Scottish Cancer Therapy Network

Trinity Park House

Edinburgh, EH5 3SQ

Tel: 0131 551 8940

Fax: 0131 552 4085